Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05425004 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib for Patients With Recurrent or Progressive Meningioma
A Phase 2 study of Meningioma, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT05425004 is a Phase 2 study of Meningioma that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 24 participants, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05425004, a Phase 2 study of Meningioma, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (3)
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05425004
The ClinicalTrials.gov registry entry for NCT05425004 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (76% lower). The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT05425004 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05425004 about?
NCT05425004 is a clinical study titled "Cabozantinib for Patients With Recurrent or Progressive Meningioma". A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
What is the current status of trial NCT05425004?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2022-06-01. Estimated completion is 2028-05.
What conditions does trial NCT05425004 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT05425004?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT05425004?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05425004 being conducted?
This trial has 3 study locations across Florida, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
Monthly SOM230C for Recurrent or Progressive Meningioma
COMPLETED · Phase 2
-
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.